Formycon
FYB.DE Small CapHealthcare · Biotechnology
Updated: Jul 6, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company's pipeline includes ustekinumab used in the treatment of Crohn's disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names. It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, hodgkin'
Formycon Stock at a Glance
Formycon (FYB.DE) is currently trading at €19.32 with a market capitalization of $341.4M. The 52-week range spans from €15.80 to €31.30; the current price is 38.3% below the yearly high. Year-over-year revenue growth stands at +147.2%.
💰 Dividend
Formycon currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
6 analysts rate Formycon (FYB.DE) on consensus: Strong Buy. The average price target is €39.67, implying +105.31% from the current price. Analyst price targets range from €30.00 to €51.00.
Formycon: The Investment Case in Detail
Formycon (FYB.DE) operates in the Healthcare — specifically Biotechnology — and is headquartered in Germany. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Top-line momentum is unusually strong with revenue expanding 147.2% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. Wall Street consensus sits at Strong Buy with an average price target implying roughly 105.31% upside from current levels — analyst sentiment is firmly constructive.
The Bear Case
Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.
What to Watch Next
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
- The analyst consensus price target implies 105.31% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Investment Thesis: Strengths & Weaknesses
- Strong revenue growth of 147.2% YoY
- Analyst consensus: Strong Buy
- –Currently unprofitable
Technical Snapshot
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Risk Profile
The data points to relatively defensive market behavior.
Trading Data
Related Stocks in the Same Sector
Formycon: the German biosimilar quiet champion riding Lucentis and Eylea expirations
The Real Story
Formycon develops biosimilar drugs in Germany and Switzerland — generic-equivalent versions of expensive biologic medicines. Its two flagship products are ranibizumab (biosimilar of Roche Lucentis, used for age-related macular degeneration) and aflibercept (biosimilar of Regeneron Eylea). Each branded original generates billions in revenue and is going off-patent in 2025 to 2027. Formycon is one of the first companies with EU and US approvals for the biosimilar versions.
The market is pricing FYB at 333 million euros market cap on 44 million euros trailing revenue — EV/Revenue 6.2. That looks expensive, but biosimilar revenue compounds dramatically as the off-patent window opens. Ranivisio and Cimerli (Formycon's brands) only launched in late 2023, so the trailing-twelve-month revenue is a fraction of the run-rate.
What Smart Money Thinks
Wilhelm Beier (former chairman, deep biotech expertise) holds a meaningful stake. Active SaaS-style PIPE investors took strategic positions in 2023. No mega-fund 13F whale. Free float is roughly 50 percent.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
📉 The 3 Real Bear Points
Valuation in Context
At 18.88 EUR the trailing P/E is undefined (negative), but forward P/E of 17.1 implies the market expects revenue to scale rapidly. EV/Revenue 6.2 is high for a small biotech, but justifiable if Lucentis-biosimilar revenue can scale to 200 to 300 million EUR annually by 2027.
🗓️ Next 3 Catalyst Dates
- :
- :
- :
💬 Daniel's Take
Biosimilar is a quietly compounding theme that the market understands but typically prices through a few large names (Sandoz, Coherus). FYB is the European pure-play. The risk is that price competition in biosimilars compresses peak margins faster than expected; the reward is the off-patent wave for Lucentis, Eylea and eventually Stelara. I would size 0.5 to 1 percent as a specialty-biotech exposure, not a core holding.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Formycon?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news